New study aims to predict dangerous immune reactions in blood cancer patients
NCT ID NCT06377059
First seen Mar 15, 2026 · Last updated May 21, 2026 · Updated 9 times
Summary
This study watches 100 adults with blood cancers like lymphoma who are getting CAR T-cell or bispecific antibody therapy. Researchers track vital signs and immune markers to find early clues that a serious complication called cytokine release syndrome (CRS) may be developing. The goal is to learn which patients need closer hospital monitoring, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Rigshospitalet
RECRUITINGCopenhagen O, 2100, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.